Grunenthal
Grunenthal GmbH, a prominent player in the pharmaceutical industry, is headquartered in Aachen, Germany. Founded in 1888, the company has established a strong presence in Europe, Latin America, and other key regions, focusing on pain management and innovative therapies. Grunenthal is renowned for its commitment to developing unique formulations and delivery systems, particularly in the field of analgesics. With a rich history marked by significant milestones, Grunenthal has pioneered several groundbreaking products that address unmet medical needs. The company’s dedication to research and development has positioned it as a leader in pain relief solutions, earning recognition for its contributions to patient care. Grunenthal continues to strive for excellence, enhancing the quality of life for patients worldwide through its specialised offerings.
DitchCarbon Score
How does Grunenthal's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grunenthal's score of 19 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Grunenthal's reported carbon emissions
In 2023, Grünenthal GmbH reported total carbon emissions of approximately 21,237,000 kg CO2e, comprising 18,137,000 kg CO2e from Scope 1 and 3,240,000 kg CO2e from Scope 2 emissions. The Scope 1 emissions included 2,822,000 kg CO2e from mobile combustion, 449,000 kg CO2e from fugitive emissions, and 1,486,000 kg CO2e from stationary combustion. In 2021, the company’s total emissions were significantly higher at about 505,821,000 kg CO2e, with Scope 1 emissions at 22,638,000 kg CO2e, Scope 2 emissions at 4,882,000 kg CO2e, and a substantial 478,301,000 kg CO2e from Scope 3 emissions. This indicates a notable reduction in emissions over the two years, particularly in Scope 3, which is often the largest contributor in many organisations. Grünenthal has committed to near-term reduction targets but has not set a net-zero target as of now. The company is actively working on its climate commitments within the pharmaceuticals, biotechnology, and life sciences sector, focusing on reducing its carbon footprint and enhancing sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | |
|---|---|---|
| Scope 1 | 22,638,000 | 00,000,000 |
| Scope 2 | 4,882,000 | 0,000,000 |
| Scope 3 | 478,301,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grunenthal is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
